Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
carnitine + aspirin
- Development stage
- Unknown
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Carnitine (also known as levocarnitine or L-carnitine) and aspirin is a combination that has potential interactions. Carnitine is a quaternary ammonium compound used to treat carnitine deficiency or to stimulate gastric and pancreatic secretions in hyperlipoproteinemia. Aspirin is a nonsteroidal anti-inflammatory drug (NSAID) used to relieve pain, reduce fever, and decrease inflammation. When combined, aspirin may decrease the excretion rate of carnitine, potentially resulting in higher serum levels of carnitine.
- Other names
- levocarnitine + aspirin
02
Targets
CaiT (Carnitine/gamma-butyrobetaine antiporter)COXSLC22A5 (Organic cation/carnitine transporter 2)SLC25A20 (Carnitine/acylcarnitine translocase)
Beyond the preview
Go deeper on carnitine + aspirin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on carnitine + aspirin.